Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 4/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20683056 | 0.80 | BTK (0.36) | KMT2ABTKBDKRB1KDM4EALDH1A1 | |
| SCHEMBL29766403 | 0.80 | BTK (0.36) | KMT2ABTKBDKRB1KDM4EALDH1A1 | |
| SCHEMBL20683066 | 0.80 | BTK (0.39) | BTKALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29766427 | 0.80 | BTK (0.39) | BTKALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL26073296 | 0.79 | BTK (0.35) | BTKALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL26073300 | 0.76 | BTK (0.34) | BTKALDH1A1CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL29766231 | 0.76 | BTK (0.34) | BTKALDH1A1CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL25489102 | 0.76 | BTK (0.34) | BTKALDH1A1CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL20533283 | 0.74 | BTK (0.34) | BTKBDKRB1 | |
| SCHEMBL30522345 | 0.74 | BTK (0.34) | BTKBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | KMT2A 1735/4885BTK 2/4885BDKRB1 966/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | KMT2A 1735/4885BTK 2/4885BDKRB1 966/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | KMT2A 1735/4885BTK 2/4885BDKRB1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.